<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293137</url>
  </required_header>
  <id_info>
    <org_study_id>NORDIC</org_study_id>
    <nct_id>NCT00293137</nct_id>
  </id_info>
  <brief_title>NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy</brief_title>
  <acronym>NORDIC</acronym>
  <official_title>Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <brief_summary>
    <textblock>
      The principal aim is to investigate the safety and efficacy of rosiglitazone in patients with&#xD;
      chronic systolic heart (Dilated cardiomyopathy). We hypothesize that in patients with heart&#xD;
      failure, rosiglitazone is safe, and can reduce nitric oxide (NO) derived oxidative stress (in&#xD;
      particular, nitrotyrosine) thereby improving endothelial dysfunction, left ventricular&#xD;
      performance, and metabolic parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a single center, double-blind, prospective placebo controlled trial of 60&#xD;
      non-diabetic heart failure patients. Prior to administration of study medication, a medical&#xD;
      history, physician exam, blood draw, laser Doppler imaging (Periscan system), venous&#xD;
      occlusion strain gauge plethysmography, metabolic exercise stress test and 2D and 3D&#xD;
      echocardiograms will be performed. Patients will then be randomized to receive rosiglitazone&#xD;
      2mg/day oral versus placebo with up-titration to 4mg/day oral versus placebo at 3 months.&#xD;
      Each study arm will have 30 patients who will participate for 6 months. Follow up assessments&#xD;
      will be completed at 6 weeks, 3 months and 6 months post randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    safety concerns regarding use of rosiglitazone&#xD;
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Primary Endpoint • Comparison of NO-derived oxidants, systemic ADMA, skin blood flow, forearm blood flow and exhaled NO. • Correlation of NO-derived oxidants, systemic ADMA, skin blood flow, forearm blood flow and exhaled NO to functional capacity</measure>
    <time_frame>120 minutes</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Systolic Heart Failure (Dilated Cardiomyopathy)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients enrolled into the trial must have left ventricular ejection fraction of &lt;40% by echocardiogram within 6 months of enrollment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        see inclusion/exclusion&#xD;
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients enrolled into the trial must meet all of the following criteria:&#xD;
&#xD;
          1. Chronic, stable, euvolemic, heart failure optimally treated for at least 3 months with&#xD;
             stable doses of ACE inhibitors or angiotensin-receptor blockers and beta-blockers&#xD;
&#xD;
          2. Mild-to-moderate signs and/or symptoms of heart failure (NYHA functional Class I-II)&#xD;
&#xD;
          3. Left ventricular ejection fraction of &lt;40% by echocardiogram within 6 months of&#xD;
             randomization or enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients meeting one or more of the following criteria are not eligible for randomization&#xD;
        into the trial:&#xD;
&#xD;
          1. Known or confirmed newly-diagnosed diabetes mellitus (2004 ADA criteria)&#xD;
&#xD;
          2. Major cardiovascular event (myocardial infarction, unstable angina, stroke, transient&#xD;
             ischemic attack, pulmonary embolism), or major surgery &lt;1 month of enrollment&#xD;
&#xD;
          3. Hospitalization or emergency room visits for heart failure exacerbation, or use of&#xD;
             inotropic agents &lt; 1 month&#xD;
&#xD;
          4. NYHA class III or IV&#xD;
&#xD;
          5. Current treatment with thiazolidinediones&#xD;
&#xD;
          6. Allergy to rosiglitazone, or liver insufficiency (ALT &gt; 2.5x upper limits of normal)&#xD;
&#xD;
          7. Heart failure due to congenital heart disease, primary valvular disease, hypertrophic&#xD;
             cardiomyopathy, or heart failure caused by known cardiotoxic agents (e.g. adriamycin)&#xD;
&#xD;
          8. End-stage renal failure on renal replacement therapy (dialysis)&#xD;
&#xD;
          9. Life expectancy, or expected cardiac transplantation within 12 months of enrollment&#xD;
&#xD;
         10. Women who are pregnant, or who are planning on becoming pregnant or are lactating.&#xD;
             Women of childbearing potential must have a negative serum pregnancy test within 48&#xD;
             hours prior to the time of randomization and must use contraceptive agents&#xD;
&#xD;
         11. Unable or unwilling to consent to all components of the protocol. Patients unwilling&#xD;
             to undergo 6-month follow-up should not be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilson H Tang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>September 18, 2008</last_update_submitted>
  <last_update_submitted_qc>September 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Anne Kanderian, MD</name_title>
    <organization>Cleveland CLinic</organization>
  </responsible_party>
  <keyword>Chronic systolic heart failure</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

